Año 2020 / Volumen 112 / Número 3
Original
The efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis

201-210

DOI: 10.17235/reed.2020.6458/2019

Zhao Li, Jie Gao, Sheng-Min Zheng, Yang Wang, Xiao Xiang, Qian Cheng, Jiye Zhu,

Resumen
Introduction: hepatocellular carcinoma (HCC) recurrence after liver resection remains a major threat for patients’ survival. Sorafenib is recommended as an adjuvant treatment for patients after a liver resection. The objective of this meta-analysis was to estimate the therapeutic value of sorafenib in patients who underwent a HCC resection. Materials and methods: relevant reports were retrieved from electronic databases. All eligible studies were carefully reviewed and the required data were extracted. Outcome with regard to overall survival (OS), recurrence-free survival (RFS), recurrence rate, mortality rate, OS time (months) and RFS time (months) were analyzed. Results: nine trials were included. The results of the meta-analysis revealed that sorafenib did not exert a significant superior effect on OS (sorafenib as reference: hazard ratio [HR] = 2.15; 95% CI, 0.91-5.08, p = 0.80; control as reference: HR = 0.56; 95% CI, 0.31-1.02; p = 0.059), OS time in months (weighted mean differences [WMD] = 4.96; 95% CI, -1.21-11.13; p = 0.115) and RFS time in months (WMD = 7.58; 95% CI, -1.36-16.53; p = 0.097). Nevertheless, the use of sorafenib was associated with a significantly higher RFS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018), and a lower recurrence rate (risk ratio [RR] = 0.72; 95% CI, 0.60-0.86; p < 0.001) and mortality rate (RR = 0.74; 95% CI, 0.57-0.95; p = 0.20). Conclusion: according to the present meta-analysis, sorafenib showed a significant benefit in RFS, recurrence rate and mortality rate. The effect of sorafenib for the prevention of HCC recurrence seems to be encouraging. However, more evidence is still needed before reaching a definitive conclusion.
Share Button
Nuevo comentario
Comentarios

12/01/2021 12:25:33
thanks


Artículos relacionados

Carta

Gastric schwannoma diagnosing gastric stromal tumor

DOI: 10.17235/reed.2023.9919/2023

Imagen en Patología Digestiva

Endoscopic resection of a descending duodenal polyp with the string-clip traction

DOI: 10.17235/reed.2022.8915/2022

Imagen en Patología Digestiva

Anemia induced by hemangioma at the duodenal papilla, resected by endoscopic mucosal resection

DOI: 10.17235/reed.2022.8439/2021

Carta

Endoscopic full-thickness resection of a gastric schwannoma

DOI: 10.17235/reed.2021.8385/2021

Imagen en Patología Digestiva

Pedunculated mucosa-associated lymphoid tissue (MALT) lymphoma causing gastric outlet obstruction

DOI: 10.17235/reed.2021.8204/2021

Carta

Rabdomiolisis en paciente en tratamiento con sorafenib

DOI: 10.17235/reed.2020.6440/2019

Carta al Editor

Utilidad de la neoadyuvancia en el manejo del GIST rectal

DOI: 10.17235/reed.2017.4751/2016

Carta al Editor

Endoscopic full-thickness resection for a gastric angioleiomyoma

DOI: 10.17235/reed.2017.4568/2016

Carta al Editor

Primary anorectal malignant melanoma: an uncommon anorectal pathology

DOI: 10.17235/reed.2016.4347/2016

Instrucciones para citar
Li Z, Gao J, Zheng S, Wang Y, Xiang X, Cheng Q, et all. The efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis. 6458/2019


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1038 veces.
Este artículo ha sido descargado 270 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 21/06/2019

Aceptado: 07/10/2019

Prepublicado: 05/02/2020

Publicado: 05/03/2020

Tiempo de revisión del artículo: 89 días

Tiempo de prepublicación: 229 días

Tiempo de edición del artículo: 258 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas